

ABSTRACT BOOK

**14th Congress of the European Society
for Organ Transplantation**

**30 August – 2 September 2009
Paris, France**

Contents

Monday, 31 August 2009

Parallel Sessions 1–18

| | | |
|---------------|---|----|
| O-1 – O-6 | Session 1. Translational research in kidney transplantation | 1 |
| O-7 – O-12 | Session 2. Large programs and registries in small bowel & liver transplantation | 2 |
| O-13 – O-18 | Session 3. Pancreas transplantation: technical aspects | 4 |
| O-19 – O-24 | Session 4. Experimental immunosuppression | 5 |
| O-25 – O-30 | Session 5. Optimisation of current immunosuppressive strategies in kidney transplantation | 7 |
| O-31 – O-36 | Session 6. Cell therapies for regeneration and immunomodulation | 9 |
| O-39 – O-47 | Session 7. Liver transplantation & tumors | 10 |
| O-48 – O-58 | Session 8. Novel pathways of recipient sensitization | 13 |
| O-59 – O-69 | Session 9. Long-term kidney graft survival parameters | 16 |
| O-70 – O-80 | Session 10. Ethical, legal and psychosocial aspects of transplantation | 18 |
| O-81 – O-91 | Session 11. Viral infections & tuberculosis in kidney transplantation | 21 |
| O-92 – O-102 | Session 12. How can we make the heart beating better? | 24 |
| O-103 – O-113 | Session 13. Infections in liver transplantation | 27 |
| O-114 – O-124 | Session 14. Operational tolerance: approaches & mechanisms | 29 |
| O-125 – O-135 | Session 15. Deceased donation: procurement, allocation, safety & best practise | 32 |
| O-136 – O-146 | Session 16. Risk factors, mechanisms & treatment of kidney humoral rejection | 35 |
| O-147 – O-157 | Session 17. Liver transplantation: immunobiology, genetics, inflammations & bioartificial devices | 38 |
| O-158 – O-168 | Session 18. Improving donor kidney quality & palliation of I/R injury | 41 |

Tuesday, 1 September 2009

Parallel Sessions 19–36

| | | |
|---------------|--|----|
| O-170 – O-174 | Session 19. Experimental & clinical islet transplantation | 45 |
| O-175 – O-180 | Session 20. Ischemia/reperfusion injury & intervention | 46 |
| O-181 – O-186 | Session 21. Long term complications in kidney transplantation | 48 |
| O-187 – O-192 | Session 22. Pediatric liver transplantation | 49 |
| O-193 – O-198 | Session 23. Mechanisms & evolution of chronic allograft nephropathy | 51 |
| O-199 – O-204 | Session 24. Clinical immunosuppression: news | 52 |
| O-205 – O-215 | Session 25. Novel insights in perfusion & preservation | 54 |
| O-216 – O-226 | Session 26. Impact of donor risk factors on kidney graft survival | 57 |
| O-227 – O-237 | Session 27. Surgical challenges in liver transplantation | 60 |
| O-238 – O-248 | Session 28. New organ donation challenge: from living donor to non heart beating donor | 63 |
| O-249 – O-259 | Session 29. Pharmaco & immunological monitoring | 66 |
| O-260 – O-270 | Session 30. New approaches to diagnostic prediction | 69 |
| O-271 – O-276 | Session 31. Cardiovascular risk factors in kidney transplantation | 71 |
| O-277 – O-282 | Session 32. Composite tissues & xenotransplantation | 73 |
| O-283 – O-288 | Session 33. How can we make the lungs breathing better? | 75 |
| O-289 – O-294 | Session 34. Pancreas transplantation: clinical aspects | 76 |
| O-295 – O-300 | Session 35. Clinical immunosuppression: renal function | 78 |
| O-301 – O-306 | Session 36. New immunosuppressive strategies in kidney transplantation | 79 |

Wednesday, 2 September 2009

Parallel Sessions 37–42

| | | |
|---------------|---|----|
| O-307 – O-312 | Session 37. Complications and outcome in liver transplantation | 82 |
| O-313 – O-318 | Session 38. Clinical immunosuppression: the liver | 84 |
| O-319 – O-324 | Session 39. Clinical immunosuppression: side effects & prevention | 85 |

| | | |
|--|--|-----|
| Contents | vii | |
| O-325 – O-330 | Session 40. Pediatric transplantation | 87 |
| O-331 – O-336 | Session 41. Belatacept in kidney transplantation | 89 |
| LB-1 – LB-6 | Session 42. Late Breaking | 91 |
| Presidential Session | | |
| O-337 – O-342 | Best Abstracts awards: Clinical Transplantation and Basic Science in Transplantation | 93 |
| Poster Presentations | | |
| Poster Session 1: Sunday, 30 August 2009 – Monday, 31 August 2009 | | |
| P-1 – P-10 | Cell transplant | 95 |
| P-11 – P-12 | Composite tissues | 97 |
| P-13 – P-57 | Donation & allocation | 97 |
| P-58 – P-107 | Clinical immunosuppression I | 109 |
| P-108 – P-136 | Experimental immunosuppression | 122 |
| P-137 – P-147 | Histocompatibility | 130 |
| P-148 – P-174 | Heart | 132 |
| P-175 – P-184 | Islets | 139 |
| P-185 – P-408 | Kidney I | 141 |
| P-409 – P-491 | Liver & intestine I | 196 |
| P-492 – P-504 | Lung | 218 |
| P-505 – P-509 | Xenotransplantation | 221 |
| Poster Session 2: Tuesday, 1 September 2009 – Wednesday, 2 September 2009 | | |
| P-510 – P-551 | Ethics, law, psychosocial & public policy | 222 |
| P-552 – P-601 | Clinical immunosuppression II | 231 |
| P-602 – P-655 | Immunobiology & basic science | 244 |
| P-656 – P-880 | Kidney II | 257 |
| P-881 – P-964 | Liver & intestine II | 312 |
| P-965 – P-982 | Pancreas | 331 |
| P-983 – P-1007 | Pediatric transplantation | 336 |
| P-1008 – P-1035 | Tissue injury & preservation | 342 |
| LBP-1 – LBP-67 | Late Breaking | 350 |
| Author Index | 367 | |